COX-2 Safety Will Be Discussed By FDA Advisory Committee In Early 2005
• By The Pink Sheet
FDA will hold an advisory committee in early 2005 to discuss the cardiovascular safety profile of COX-2 inhibitors, Acting Deputy Commissioner of Operations Janet Woodcock, MD, said at an American College of Rheumatology meeting Oct. 18 in San Antonio
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights